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Introduction
Childhood obesity prevalence has increased 
substantially in the past several decades 
(Ogden and Carroll 2010). In the United 
States, 16.9% of children 2–19 years of age 
are obese (Ogden et al. 2014). Compared 
with normal-weight children, obese children 
are at greater risk of becoming obese adults 
(Freedman et al. 2005), with associated risks 
of diabetes, heart disease, cancer, and many 
other ailments. Evidence suggests that factors 
in addition to energy balance have contrib-
uted to the obesity epidemic (Keith et al. 
2006). The concomitant increase in obesity 
rates with increased production and use of 
synthetic chemicals in consumer products has 
led to a search for environmental causes of 
obesity (Baillie-Hamilton 2002). Xenobiotic 
chemicals, such as endocrine disruptors, are 
thought to be “environmental obesogens” 
that promote obesity through dysregulation of 
lipid metabolism and adipogenesis (Grün and 
Blumberg 2006).
Phthalates, synthetic chemicals with 
 endocrine-disrupting propert ies ,  are 
hypothesized to be obesogens (Desvergne 
et al. 2009; Kim and Park 2014). Human 
exposure to phthalates is ubiquitous, arising 
from contact with a wide range of consumer 
products, including building materials, medical 
devices, pharmaceuticals, toys, food packaging, 
cosmetics, and fragrances (Schettler 2006). 
Phthalate metabolites have been detected in 
amniotic fluid (Silva et al. 2004; Wittassek 
et al. 2009), and early-life phthalate exposures 
have been associated with health outcomes in 
childhood, including physical and neurological 
development, allergic diseases, and anogenital 
distance in boys (reviewed by Braun et al. 
2013). Dibutyl (DnBP), di-iso-butyl (DiBP), 
di-iso-nonyl (DiNP), benzylbutyl (BzBP), and 
di(2-ethylhexyl) (DEHP) phthalates exhibit 
anti-androgenic activity (National Research 
Council 2008), and phthalate associations for 
some developmental end points have been 
reported to vary by sex (Engel et al. 2009; Swan 
et al. 2010; Wolff et al. 2008).
Phthalate exposures during gestation 
are hypothesized to affect production and 
accumulation of body fat by modifying 
peroxisome proliferator–activated receptors 
(PPARs), associated with adipogenesis, 
lipid and carbohydrate metabolism, and 
androgen levels, or by disrupting thyroid 
hormone function (Desvergne et al. 2009; 
Kim and Park 2014). Potential effects of anti-
androgenic phthalates may differ between girls 
and boys given that sex steroids are associ-
ated with sexually dimorphic development of 
adipose tissue (Grün and Blumberg 2009).
Although a number of studies, primarily 
cross-sectional, have reported associations 
between urinary phthalate metabolite concen-
trations and body size in children (recently 
reviewed by Goodman et al. 2014), only 
one previous study has examined gestational 
exposure, a hypothesized critical window for 
an effect of phthalates on obesity. Valvi et al. 
(2015) assessed associations between prenatal 
phthalate exposures and childhood body size 
in a Spanish birth cohort and reported sex-
specific associations of high-, but not low-, 
molecular-weight phthalates with infant 
weight gain and body mass index (BMI) 
z-scores at ages 1, 4, and 7 years (inverse 
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Background: Experimental animal studies and limited epidemiologic evidence suggest that 
prenatal exposure to phthalates may be obesogenic, with potential sex-specific effects of phthalates 
having anti-androgenic activity. 
oBjectives: We aimed to assess associations between prenatal phthalate exposures and childhood 
fat mass in a prospective cohort study.
Methods: We measured phthalate metabolite concentrations in third-trimester maternal urine 
in a cohort of women enrolled in New York City between 1998 and 2002 (n = 404). Among 180 
children (82 girls and 98 boys), we evaluated body composition using a Tanita scale at multiple 
follow-up visits between ages 4 and 9 years (363 total visits). We estimated associations of standard 
deviation differences or tertiles of natural log phthalate metabolite concentrations with percent fat 
mass using linear mixed-effects regression models with random intercepts for repeated outcome 
measurements. We assessed associations in multiple metabolite models and adjusted for covari-
ates including prepregnancy body mass index, gestational weight gain, maternal smoking during 
 pregnancy, and breastfeeding.
results: We did not observe associations between maternal urinary phthalate concentrations 
and percent body fat in models examining continuous exposures. Fat mass was 3.06% (95% CI: 
–5.99, –0.09%) lower among children in the highest tertile of maternal urinary concentrations of 
summed di(2-ethylhexyl) phthalate (∑DEHP) metabolites than in children in the lowest tertile. 
Though estimates were imprecise, there was little evidence that associations between maternal 
urinary phthalate concentrations and percent fat mass were modified by child’s sex.
conclusions: Prenatal phthalate exposures were not associated with increased body fat among 
children 4–9 years of age, though high prenatal DEHP exposure may be associated with lower fat 
mass in childhood.
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among boys, positive among girls). However, 
BMI is a measure of excess weight for height 
and does not distinguish between lean and 
fat mass (Freedman and Sherry 2009). To 
address this gap, we assessed the associations 
between third-trimester urinary phthalate 
metabolite concentrations and body compo-
sition estimates of percent fat mass at ages 
4–9 years in a prospective birth cohort.
Methods
Study population.  The Mount Sinai 
Children’s Environmental Health Study 
enrolled 479 primiparous women with 
singleton pregnancies from the Mount Sinai 
Diagnostic and Treatment Center and two 
adjacent private practices in New York City 
between 1998 and 2002. Women delivered 
at the Mount Sinai Medical Center, and 
75 women were subsequently excluded for 
reasons described elsewhere (Engel et al. 
2007). The final birth cohort consists of 404 
infants for whom birth data were available. 
Children were invited to return for three 
follow-up visits scheduled at approximately 
ages 4–5.5 (mean, 4.9), 6 (mean, 6.2), and 
7–9 (mean, 7.8) years, hereafter referred to as 
visits 1, 2, and 3, respectively.
Of the 404 infants in the birth cohort, 382 
had prenatal phthalate metabolite concentra-
tions measured in maternal urine. Following 
previous work (Wolff et al. 2008), we excluded 
two observations obtained from a very dilute 
urine (< 10 mg/dL creatinine) because of the 
potential for inaccurate biomarker measure-
ments. Of the remaining 380 infants, the 
present analysis includes 180 with at least one 
outcome measurement at follow-up (363 total 
visits for percent fat mass, 364 total visits for 
supplementary BMI analysis).
Women provided written informed 
consent before participation and children 
≥ 7 years of age provided assent. The study 
received approval from the Mount Sinai 
School of Medicine Institutional Review 
Board. The involvement of the Centers for 
Disease Control and Prevention (CDC) 
laboratory was determined not to constitute 
engagement in human subjects research. The 
University of North Carolina at Chapel Hill 
Institutional Review Board approved the 
present analysis.
Phthalate exposures. Mothers provided a 
spot urine sample between 25 and 40 weeks’ 
gestation (mean, 31.5 weeks). Samples were 
analyzed at the CDC laboratory for the 
following phthalate metabolites: monoethyl 
phthalate [MEP, a metabolite of diethyl 
phthalate (DEP)], mono-n-butyl phthalate 
(MnBP, a metabolite of DnBP), monoiso-
butyl phthalate (MiBP, a metabolite of 
DiBP), mono(3-carboxypropyl) phthalate 
(MCPP, a nonspecific metabolite of several 
high molecular weight phthalates and a minor 
metabolite of DnBP), monobenzyl phthalate 
(MBzP, a metabolite of BzBP), and four 
metabolites of DEHP: mono(2-ethylhexyl) 
phthalate (MEHP), mono(2-ethyl-5-
hydroxyhexyl) phthalate (MEHHP), mono(2-
ethyl-5-oxohexyl) phthalate (MEOHP), and 
mono(2-ethyl-5-carboxypentyl) phthalate 
(MECPP). Laboratory and quality control 
methods have been reported previously (Kato 
et al. 2005). Correction factors were applied 
to MBzP (0.72) and MEP (0.66) concentra-
tions and limits of detection (LOD) to adjust 
for inaccuracies in analytical standards (CDC 
2012). Distributions of prenatal phthalate 
metabolite concentrations were similar among 
children with and without a follow-up visit 
(Engel et al. 2010).
Outcome assessment. At each follow-
up visit, we measured children in bare or 
stocking feet wearing a pediatric gown or 
light clothing. We assessed weight and body 
composition via bioelectrical impedance 
analysis using a pediatric Tanita scale (model 
TBF-300; Tanita Corporation of America). 
We obtained duplicate measures of height 
using a stadiometer, and collected a third 
measure if the difference between the first two 
measures exceeded 2.0 cm.
Using the fat mass estimates reported by 
the Tanita scale, we calculated percent fat mass 
as (fat mass/weight) × 100. Because the Tanita 
equations for fat mass have not been validated 
for children < 7 years of age, we tested two 
alternative equations validated for estimating 
fat mass from bioelectrical impedance measures 
in children (Clasey et al. 2011; Horlick et al. 
2002). The Horlick et al. (2002) equation 
performed poorly in this sample and yielded 
many percent fat mass values that exceeded 
total mass (data not shown). Percent fat mass 
values estimated with the Clasey et al. (2011) 
equation were highly correlated with the 
Tanita values (Pearson R2 = 0.97) but yielded 
some implausible estimates. Thus, we used the 
Tanita proprietary equations. For supplemen-
tary analyses, we also calculated BMI as weight 
(kilograms)/height (meters)2 and determined 
age- and sex-standardized BMI z-scores using a 
CDC SAS macro (CDC 2004).
Covariates. We collected covariate data 
from mothers during a 2-hr structured inter-
view at enrollment. We ascertained pregnancy 
and delivery characteristics from a comput-
erized perinatal database at Mount Sinai 
Hospital. We calculated adequacy of gesta-
tional weight gain as the ratio of observed 
gestational weight gain (last pregnancy weight 
minus self-reported prepregnancy weight) to 
expected gestational weight gain based on 
the 2009 Institute of Medicine recommenda-
tions × 100 (IOM/NRC 2009). For tabular 
presentation, we categorized gains as less 
than recommended (< 86%), recommended 
(86–120%), or more than recommended 
(> 120%) (Bodnar et al. 2011). We classi-
fied physical activity at each follow-up visit 
as active if the parent/caretaker reported the 
child was “active most of the time” or inactive 
if the child was “active some of the time” or 
“hardly at all.”
Statistical analysis. We used a Bayesian 
modeling framework to assess associations 
between prenatal phthalate metabolite concen-
trations and percent fat mass. We selected 
this approach to estimate associations while 
simultaneously addressing several potential 
biases by a) imputing metabolite concentra-
tions below the LOD, b) stabilizing estimates 
from multiple metabolite models, c) imputing 
missing covariate data, and d) examining 
potentially informative loss to follow-up.
First,  we accounted for phthalate 
metabolite concentrations below the LOD 
by imputing values from a truncated normal 
distribution (Carmichael et al. 2010; Uh 
et al. 2008). At each iteration of the Markov 
chain Monte Carlo (MCMC) algorithm, we 
imputed natural log values of each metabolite 
from a truncated normal distribution with 
parameters defined as the mean and standard 
deviation (SD) of the observed distribution, 
a lower bound of 0, and an upper bound set 
equal to the LOD (WinBUGS package djl.
dnorm.trunc). Because DEHP metabolites 
(MECPP, MEHHP, MEHP, MEOHP) 
represent exposure from the same sources and 
are highly correlated (Wolff et al. 2008), we 
examined them as a molar sum (ΣDEHP) 
that was computed using component metab-
olite values at each MCMC iteration. We 
standardized the natural log of each phthalate 
metabolite or sum to its mean and SD to 
facilitate comparison of estimated relative 
phthalate effect sizes in relation to their 
 distribution in the study population.
Phthalate metabolite concentrations are 
correlated because they have common parent 
phthalates and source products, suggesting 
that estimates of association between percent 
fat mass and an individual phthalate metabo-
lite may be confounded by other metabo-
lites. Therefore, we estimated associations 
in multiple metabolite hierarchical models 
within our Bayesian framework. We gave the 
beta coefficient of each standardized phthalate 
metabolite an independent normal prior 
distribution with a mean of zero and variance 
of 1/τ2 (MacLehose et al. 2007). We selected 
a value of τ that reflects our prior belief that 
95% of the effects of a SD difference in 
natural log phthalate metabolite concentra-
tion are within approximately ± 1 SD of the 
mean percent fat mass in the study popula-
tion (τ = 1/16). As a sensitivity analysis, we 
estimated associations using single metabolite 
models that specified the same prior distri-
butions for phthalate beta coefficients but 
included only one metabolite at a time.
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We adjusted for potential confounding 
variables identified using directed acyclic 
graphs  ( see  Supplementa l  Mater ia l , 
Figure S1). Demographic and socio economic 
characteristics included maternal race/
ethnicity (non-Hispanic white/non-Hispanic 
black/Hispanic), age, education (less than 
college/college degree or more), and work 
status during pregnancy (employed/student or 
homemaker). We adjusted for maternal body 
size characteristics (prepregnancy BMI and 
adequacy of gestational weight gain), maternal 
smoking during pregnancy (yes/no), and 
breastfeeding (ever/never) to account for early-
life factors that are associated with childhood 
overweight status (Weng et al. 2012). We 
adjusted for calendar date of urine collection 
to account for temporal trends in phthalate 
exposure and prevalence of childhood obesity. 
Additionally, we adjusted for natural log creat-
inine (to account for urine dilution), child’s 
sex, months of age at follow-up, and a product 
term between child’s sex and months of age at 
follow-up. We also included strong predictors 
of the outcome, including maternal height 
and child physical activity at follow-up (active/
inactive), to improve precision. We evaluated 
child’s sex as an effect measure modifier by 
including a product term between sex and 
each metabolite. We standardized continuous 
covariates (maternal age, prepregnancy BMI, 
maternal height, adequacy of gestational 
weight gain, calendar date of urine collection, 
natural log creatinine, and age at follow-up) 
as (x – μx)/(2σx) to improve MCMC conver-
gence and facilitate comparisons of estimated 
effect sizes with dichotomous covariates 
(Gelman et al. 2013). We used higher-order 
polynomials to model maternal age (cubic), 
maternal prepregnancy BMI (quadratic), 
adequacy of gestational weight gain (cubic), 
and natural log creatinine (quadratic) based 
on visual assessment of associations between 
covariates and percent fat mass using gener-
alized additive models (SAS PROC GAM; 
SAS Institute Inc.) and likelihood ratio tests 
assessing improvement in model fit. We speci-
fied independent null-centered priors with 
τ = 1/64 for each covariate, reflecting our prior 
belief that 95% of the effects of binary covari-
ates (or a 2-SD change in continuous covari-
ates) are within ± 2 SDs of the mean percent 
fat mass in the study population.
Again taking advantage of the Bayesian 
framework for multiple imputation, we 
imputed missing values for adequacy of gesta-
tional weight gain (n = 22), breastfeeding 
(n = 1), and physical activity at follow-up 
(n = 3 children with eight visits) within the 
MCMC procedure under the assumption that 
values are missing at random. Because missing 
adequacy of gestational weight gain was attrib-
utable to missing last pregnancy weights, we 
modeled last pregnancy weight as a normally 
distributed random variable conditional on 
maternal education, race/ethnicity, child’s 
sex, smoking during pregnancy, work status 
during pregnancy, maternal age at delivery, 
birth weight, maternal height, gestational age, 
maternal first pregnancy weight, and maternal 
prepregnancy BMI. At each iteration of the 
MCMC algorithm, adequacy of gestational 
weight gain was calculated using the imputed 
last pregnancy weight. We modeled breast-
feeding using a logistic model conditional on 
maternal education, race/ethnicity, child’s 
sex, smoking during pregnancy, work status 
during pregnancy, maternal age at delivery, 
adequacy of gestational weight gain, maternal 
prepregnancy BMI, and birth weight. We 
modeled physical activity at each follow-up 
visit using a logistic mixed effects model 
with random intercepts, conditional on 
race/ethnicity, maternal prepregnancy BMI, 
smoking during pregnancy, age at follow-
up (months), birth weight, and child’s sex. 
We gave beta coefficients in the imputation 
models independent, null-centered priors 
with τ = 1, reflecting our prior belief that 
95% of the effects of binary covariates (or a 
2-SD change in continuous covariates) are 
within ± 2 SDs of the mean last pregnancy 
weight or within an odds ratio of 0.14–7.1 for 
breastfeeding and physical activity.
We assessed associations of third-trimester 
maternal urinary phthalate metabolite 
concentrations with percent fat mass using 
linear mixed-effects regression models with 
random intercepts to account for multiple 
observations per child. We estimated poste-
rior mean beta coefficients and 95% credible 
intervals (CI) per SD increase in natural log 
phthalate metabolite concentrations. The 
interpretation of a CI is more intuitive than 
that of a confidence interval from a conven-
tional analysis; specifically, given the data and 
the model, there is a 95% chance that the 
true value is within this interval. In models 
examining modification by child’s sex, we 
included product terms between sex and 
each metabolite, as well as between sex and 
natural log creatinine, and considered there 
to be meaningful modification if the 80% CI 
did not cross the null value. To assess poten-
tial nonlinear dose–response relationships, 
we also fit models with indicator variables 
for the second and third tertile categories 
of each metabolite (tertile classification was 
based on metabolite distributions among the 
180 children in the sample). To account for 
urine dilution in these analyses, we catego-
rized exposure using creatinine-corrected 
concentrations (micrograms per gram creati-
nine for metabolites or micromoles per gram 
creatinine for ∑DEHP) and did not include 
natural log creatinine as a covariate.
To assess a second measure of child-
hood adiposity and facilitate comparisons 
to studies without body composition data, 
we also estimated associations between 
phthalate metabolite concentrations and 
BMI z-scores using the statistical approach 
described above.
We ran each of the final Bayesian models 
for 50,000 iterations after an initial 10,000 
iteration burn-in, and assessed model conver-
gence using standard diagnostic measures 
described elsewhere (Gelman et al. 2013). 
We created causal diagrams using DAGitty 
version 2.2 (Textor et al. 2011), conducted 
descriptive analyses in SAS version 9.3 (SAS 
Institute Inc.), and performed Bayesian 
modeling in WinBUGS version 1.4.3 (MRC 
Biostatistics Unit).
Sensitivity analysis for loss to follow-up. 
Our primary analyses of children with at least 
one follow-up visit (n = 180) assumed that 
responses were missing-at-random condi-
tional on observed outcomes and covariates. 
Because there were some differences in the 
distribution of observed variables between 
the birth cohort and the follow-up sample 
(Engel et al. 2010) and because the prob-
ability of a missing fat mass measure may 
depend upon its true (unobserved) value, 
we assessed the sensitivity of our findings to 
potential selection bias. We used a selection 
model approach (Little and Rubin 2002) 
to model the association between phthalate 
exposures and percent fat mass among all 380 
children with measured prenatal phthalate 
metabolite concentrations, under a poten-
tially nonignorable (missing not at random) 
missing data mechanism. For this analysis, 
we jointly fit our model for percent fat mass 
with a logistic model for a binary indicator 
of whether the outcome value was missing at 
each follow-up visit. The missing data indi-
cator model was dependent on the possibly 
unobserved percent fat mass value as well as 
covariates either observed or expected to be 
associated with loss to follow-up (maternal 
age at delivery, race/ethnicity, prepregnancy 
BMI, adequacy of gestational weight gain, 
child’s sex, months of age at follow-up). 
Because results from selection models are 
sensitive to the assumed missing data mecha-
nism (Little 1995), we explored models with 
additional covariates in the missing data 
indicator model (maternal smoking during 
pregnancy, breastfeeding, maternal educa-
tion, work status during pregnancy, birth 
weight) and varied parameterization of 
continuous variables. Beta coefficients were 
given null-centered, independent priors with 
τ = 2 to reflect our prior belief that 95% of 
the effects of a binary covariate (or a 2-SD 
change in continuous covariates) are within 
an odds ratio of 0.25–4. We ran 10 chains 
for inference from the MCMC procedure 
and compared results to models that assumed 
dropout was missing at random.
Buckley et al.
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Results
Although baseline characteristics of children 
included in the study sample were similar 
to those in the birth cohort, there were 
minor differences (Table 1). For example, 
children of mothers with younger maternal 
age, underweight prepregnancy BMI, and 
less than recommended gestational weight 
gain were more likely to be lost to follow-
up. All phthalate metabolites were detected 
in > 90% of third-trimester maternal urine 
samples and geometric mean concentrations 
were somewhat higher than reported among 
females ≥ 6 years of age in the 2001–2002 
National Health and Nutrition Examination 
Survey (CDC 2015), a nationally representa-
tive sample of U.S. females during a similar 
time frame (Table 2).
Twenty-one percent of the children were 
classified as obese during at least one follow-
up visit (19% at visit 1, 14% at visit 2, and 
22% at visit 3). Percent fat mass increased with 
age and differed by child’s sex, with a larger 
SD among girls than among boys at all ages 
(Table 3). As expected, BMI z-score distribu-
tions were less variable as they are age- and 
sex-standardized (see Supplemental Material, 
Table S1). Correlations between percent fat 
mass and BMI z-scores increased with age; 
Spearman R2s were 0.75, 0.82, and 0.91 and 
the first, second, and third visits, respectively.
Estimates of association between stan-
dardized natural log phthalate metabolite 
concentrations and percent fat mass are 
reported in Table 4. All 95% CIs included 
the null value and no associations were 
modified by child’s sex (i.e., all 80% CIs 
for phthalate × sex product terms included 
the null value), though estimates were 
imprecise. In models assessing metabolite 
tertiles, there was an inverse relationship 
for the association of ∑DEHP with percent 
fat mass (Figure 1). Compared with the 
lowest ∑DEHP tertile, fat mass was 1.77% 
(95% CI: –4.48, 0.97%) lower in the middle 
tertile and 3.06% (95% CI: –5.99, –0.09%) 
lower in the highest tertile. We found 
no evidence of associations between tertile 
categories of other metabolites and percent 
fat mass, nor evidence of differences in asso-
ciations of phthalate tertiles with percent fat 
mass by child’s sex, though CIs were wide 
(see Supplemental Material, Table S2).
Results of sensitivity analyses are reported 
in Table 5. Associations estimated in multiple 
and single metabolite models were similar, 
though the multiple metabolite model beta 
coefficients tended to be slightly farther from 
the null and CIs were less precise. Results 
of the sensitivity analysis for loss to follow-
up indicated that missing fat mass data may 
indeed be nonignorable (i.e., the probability 
of follow-up depends on the child’s poten-
tially unobserved percent fat mass value). 
Children with more fat mass were less likely 
to be lost to follow-up: For each 1% increase 
in fat mass, the odds ratio for loss to follow-
up was 0.81 (95% CI: 0.69, 0.94). However, 
associations between phthalate metabolites 
and percent fat mass estimated in a selection 
model accounting for nonignorable missing 
outcomes were similar to the primary analysis 
Table 1. Characteristics of participants at birth and follow-up, Mount Sinai Children’s Environmental 
Health Study 1998–2002.
Characteristic
Birth cohort 
n (%)
Study sample 
n (%)
Total (n) 404 180
Race/ethnicity
Non-Hispanic white 86 (21.3) 34 (18.9)
Non-Hispanic black 112 (27.7) 51 (28.3)
Hispanic or other 206 (51) 95 (52.8)
Maternal age at delivery (years)
< 20 142 (35.2) 56 (31.1)
20–24 132 (32.7) 60 (33.3)
25–29 44 (10.9) 26 (14.4)
≥ 30 86 (21.3) 38 (21.1)
Maternal education (≥ college degree) 100 (24.8) 40 (22.2)
Maternal work status (employed) 235 (58.2) 107 (59.4)
Maternal smoking during pregnancy 67 (16.6) 31 (17.2)
Maternal prepregnancy BMI (kg/m2)
< 18.5 82 (20.3) 10 (5.6)
18.5–24.9 215 (53.2) 111 (61.7)
25–29.9 72 (17.8) 42 (23.3)
≥ 30 35 (8.7) 17 (9.4)
Maternal height (m) (mean ± SD) 1.63 ± 0.07 1.62 ± 0.08
Adequacy of gestational weight gain
Less than recommended 44 (12.3) 14 (8.9)
Recommended 75 (21) 40 (25.3)
More than recommended 238 (66.7) 104 (65.8)
Missing 47 22
Year of maternal urine collection
1998 84 (21.9) 34 (18.9)
1999 127 (33.2) 55 (30.6)
2000 134 (35) 72 (40)
2001 35 (9.1) 18 (10)
2002 3 (0.8) 1 (0.6)
Urine not collected 21 0
Child’s sex (male) 222 (55) 98 (54.4)
Breastfed
Ever 206 (63) 113 (63.1)
Never 121 (37) 66 (36.9)
Missing 77 1
Physical activity at follow-upa
Inactive 100 (56.5)
Active most of the time 77 (43.5)
Missing 3
aProportion classified as inactive at any follow-up visit.
Table 2. Distributions of phthalate metabolite concentrations (μg/L) in third trimester maternal urine 
samples (n = 180), Mount Sinai Children’s Environmental Health Study 1998–2002.
Metabolite (μg/L) LOD
Percent 
detected
Geometric 
meana Minimum
25th 
percentile
75th 
percentile Maximum NHANESb
MEP 0.26 99.4 223 < LOD 87.1 525 29,528 115
MnBP 0.4 100 32.9 0.800 14.3 79.5 4,043 20.2
MiBP 0.26 97.8 5.83 < LOD 2.90 15.1 76.6 2.68
MCPP 0.16 97.8 2.87 < LOD 1.50 6.30 129 2.62
MBzP 0.08 99.4 14.1 < LOD 5.70 32.8 481 10.5
∑DEHPc NA NA 0.284 < LOD 0.125 0.530 19.9
MECPP 0.25 99.4 36.0 < LOD 15.1 72.7 2,055 31.9d
MEHHP 0.32 99.4 21.0 < LOD 8.80 41.3 2,051 18.3
MEHP 0.9 91.7 6.15 < LOD 3.00 14.2 478 4.23
MEOHP 0.45 99.4 18.7 < LOD 8.20 38.3 1,335 12.5
Abbreviations: NA, not available; NHANES, National Health and Nutrition Examination Survey.
aTo compute the geometric mean, phthalate metabolite concentrations < LOD were replaced by LOD divided by the 
square root of 2. bGeometric mean phthalate metabolite concentrations among 1,411 female NHANES 2001–2002 
participants age ≥ 6 years (CDC 2015). c∑DEHP is expressed as micromoles/L. dMECPP was not included in NHANES 
2001–2002; data are from NHANES 2003–2004 (n = 1,355).
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(Table 5). Varying parameters in the missing 
data indicator model did not alter results 
(data not shown).
Patterns of association between phthalate 
metabol i te  concentrat ions  and BMI 
z-scores were generally consistent with our 
analyses of percent fat mass, though esti-
mates were attenuated toward the null (see 
Supplemental Material, Table S3). Notably, 
we did not observe associations between 
∑DEHP metabolite concentrations and BMI 
z-scores in continuous or tertile models (see 
Supplemental Material, Table S3).
Discussion
In this prospective study of gestational 
phthalate exposures and adiposity in 
childhood, we did not observe associa-
tions between continuously modeled third 
trimester maternal urinary phthalate metabo-
lite concentrations and percent fat mass. 
On average, children in the highest tertile 
of ∑DEHP metabolites had approximately 
3% lower fat mass at ages 4–9 years than 
did children in the lowest tertile of ∑DEHP 
metabolites. We did not observe notable 
modification of associations by child’s sex, 
though there is limited ability to detect 
heterogeneity in this small sample. Findings 
were robust to adjustment for a comprehen-
sive set of confounders and to a sensitivity 
analysis assessing bias from loss to follow-up.
Our findings suggest an anti-adipogenic 
effect of DEHP exposure, which is consistent 
with toxicological studies reporting that rela-
tively high-dose postnatal DEHP exposure 
(doses equivalent to 2% of the animal’s body 
weight) induces PPARα-mediated reduc-
tions in body weight and fat mass in both 
rats (Itsuki-Yoneda et al. 2007) and mice (Xie 
et al. 2002). However, toxicological studies 
examining early-life exposure to DEHP or its 
hydrolytic metabolite, MEHP, have reported 
species- and dose-specific effects on subsequent 
body fat of offspring. Two studies of perinatal 
MEHP or DEHP exposure in mice reported 
increased body weight and fat deposition in 
offspring, though one study observed effects 
only at the lowest dose administered (0.05 
but not 0.25 or 0.5 mg MEHP/kg/day) (Hao 
et al. 2012), and the other reported effects 
at both low and high doses (0.05 and 5 mg 
DEHP/kg/day) (Schmidt et al. 2012). Two 
studies of pregnant rats exposed to doses 
ranging from 1 to 400 mg DEHP/kg/day 
reported no difference in offspring total body 
weight (Campioli et al. 2014; Kobayashi 
et al. 2006). Interestingly, Feige et al. (2010) 
reported that although high dose DEHP 
exposure (500 mg/kg body mass/day) protected 
against diet-induced obesity via PPARα activa-
tion in wild-type mice, mice with humanized 
PPARα gained more weight and adipose tissue 
than untreated controls. Although the causes 
of species differences remain unclear, effects 
of DEHP on other, less understood pathways 
(e.g., liver metabolism, thyroid function, 
androgen activity) may play a role.
A study that examined DEHP metabo-
lite concentrations in cord plasma in relation 
to repeated BMI measurements in the first 
year of life reported associations of one 
Table 3. Percent fat mass distributions in the Mount Sinai Children’s Environmental Health Study.a
Visit
Age (years) 
(mean ± SD
Overall Girls Boys
n Mean ± SD n Mean ± SD n Mean ± SD
All visits 6.5 ± 1.3 363 18.4 ± 8.4 173 17.5 ± 9.8 190 19.3 ± 6.8
Visit 1 4.9 ± 0.4 97 15.3 ± 7.5 47 12.6 ± 8.8 50 17.8 ± 4.8
Visit 2 6.1 ± 0.2 117 17.5 ± 7.2 57 16.4 ± 8.6 60 18.5 ± 5.4
Visit 3 7.8 ± 0.8 149 21.2 ± 9.0 69 21.6 ± 9.8 80 20.9 ± 8.3
aPercent fat mass estimated using bioelectrical impedance analysis (Tanita TBF-300).
Table 4. Adjusted associations between third trimester maternal urinary phthalate metabolite concentra-
tions and percent fat mass among children age 4–9 years in the Mount Sinai Children’s Environmental 
Health Study.
Metabolite Overall Girls Boysa
MEP 0.12 (–1.34, 1.58) –0.35 (–2.43, 1.75) 0.75 (–1.31, 2.80)
MnBP –0.86 (–3.07, 1.36) –0.34 (–3.71, 3.05) –0.86 (–3.46, 1.74)
MiBP 0.34 (–1.54, 2.20) 1.04 (–1.36, 3.44) –0.88 (–3.44, 1.68)
MCPP 0.63 (–1.55, 2.82) 1.21 (–1.44, 3.87) –0.08 (–3.22, 3.03)
MBzP 0.67 (–1.31, 2.65) 0.62 (–1.77, 3.02) 0.98 (–2.17, 4.14)
∑DEHP –0.89 (–2.24, 0.47) –0.80 (–2.81, 1.23) –0.64 (–2.46, 1.16)
Beta coefficients (95% credible intervals) per standard deviation increase in natural log phthalate metabolite concen-
trations were estimated in a multiple metabolite linear mixed-effects regression model. Sex-specific estimates were 
modeled by including product terms for phthalate × child’s sex. Estimates are adjusted for urine dilution and collection 
date; maternal race/ethnicity, age, education, work status, and smoking during pregnancy; maternal height and prepreg-
nancy BMI; adequacy of gestational weight gain; breastfeeding; months of age and physical activity at follow-up; and, 
for overall models, child’s sex.
aSex-specific estimates did not meet criteria for heterogeneity (i.e., 80% credible intervals for all phthalate × sex product 
terms included the null value).
Table 5. Sensitivity analyses for associations between third trimester maternal urinary phthalate metabo-
lite concentrations and percent fat mass among children 4–9 years of age in the Mount Sinai Children’s 
Environmental Health Study.
Metabolite Primary analysisa Single metabolite modelsb Loss to follow-upc
MEP 0.12 (–1.34, 1.58) 0.08 (–1.14, 1.30) –0.12 (–1.62, 1.36)
MnBP –0.86 (–3.07, 1.36) –0.07 (–1.41, 1.27) –0.93 (–3.15, 1.30)
MiBP 0.34 (–1.54, 2.20) 0.23 (–1.12, 1.52) 1.03 (–0.91, 2.97)
MCPP 0.63 (–1.55, 2.82) 0.30 (–1.05, 1.66) 0.40 (–1.81, 2.60)
MBzP 0.67 (–1.31, 2.65) 0.40 (–0.93, 1.74) 0.48 (–1.47, 2.47)
∑DEHP –0.89 (–2.24, 0.47) –0.57 (–1.79, 0.57) –0.62 (–2.01, 0.81)
Beta coefficients (95% credible intervals) per SD increase in natural log phthalate metabolite concentrations, adjusted 
for urine dilution and collection date; maternal race/ethnicity, age, education, work status, and smoking during preg-
nancy; maternal height and prepregnancy BMI; adequacy of gestational weight gain; breastfeeding; months of age and 
physical activity at follow-up; and child’s sex.
aAssociations among children with at least one follow-up visit (n = 180) estimated in a multiple metabolite linear 
mixed-effects regression model. bAssociations among children with at least one follow-up visit (n = 180) estimated in a 
separate linear mixed-effects regression model for each metabolite. cAssociations among all children in the birth cohort 
with measured phthalate metabolite concentrations (n = 380) estimated in a multiple metabolite linear mixed-effects 
regression model using a selection model for potentially nonignorable missing outcome data.
Figure 1. Adjusted associations between tertiles of third trimester maternal urinary phthalate metabolite 
concentrations and percent fat mass among children 4–9 years of age in the Mount Sinai Children’s 
Environmental Health Study. ref, reference.
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metabolite, MEOHP, with lower BMI in boys 
(de Cock et al. 2014). However, this study 
was based on a small sample at each time 
point (n < 10). Further, the use of phthalate 
metabolite concentrations in blood or blood 
products as exposure biomarkers is ques-
tionable (Calafat et al. 2013). Although the 
authors measured only secondary or oxidative 
metabolites, which may reflect true biological 
exposures, it is possible that cord plasma 
DEHP metabolites arise from hospital-based 
exposures to DEHP at the time of delivery 
(Yan et al. 2009). Valvi et al. (2015) examined 
associations between the average of first- and 
third-trimester maternal urinary phthalate 
metabolites concentrations and difference 
in weight gain z-score in the first 6 months, 
BMI z-scores at ages 1, 4, and 7 years, and 
waist-to-height ratio at ages 4 and 7 years in 
a Spanish birth cohort (n = 391). Associations 
between summed high-molecular-weight 
phthalates concentrations (four DEHP metab-
olites and MBzP) and infant weight gain and 
BMI z-scores were inverse among boys but 
positive among girls (supplementary analyses 
indicated these associations were attributable 
to ∑DEHP and not MBzP). Similar to our 
findings, Valvi et al. (2015) did not identify 
associations between prenatal concentrations 
of low-molecular-weight phthalate metabolites 
and childhood body size. Although we had 
low power to detect sex differences in associa-
tions of ∑DEHP metabolites with percent fat 
mass, estimates comparing the highest with 
lowest tertiles of ∑DEHP metabolites were 
very similar among boys (β: –2.99%; 95% CI: 
–7.10, 1.15%) and girls (β: –3.07%; 95% CI: 
–6.54, 0.41%).
A number of cross-sectional analyses 
have examined phthalate exposures and 
obesity, BMI, waist circumference, or related 
measures in humans (recently reviewed by 
Goodman et al. 2014). Many of these studies 
reported associations between phthalate 
metabolites and adiposity-related outcomes, 
with results often differing between groups 
defined by age, sex, race/ethnicity, or other 
characteristics. Such cross-sectional analyses 
are problematic because it is unclear whether 
phthalate exposures are causally related to 
obesity or phthalate body burden differs 
in obese individuals due to differences in 
exposure to phthalate sources, such as diet 
(Serrano et al. 2014), personal care products 
(Buckley et al. 2012), or medications 
(Hernández-Díaz et al. 2013). In addition, 
these analyses did not assess exposures during 
gestation, a hypothesized critical window for 
an effect of phthalates on pathways related to 
development of obesity.
Phthalates have relatively short half-lives 
and are excreted in urine in < 24 hr (Koch 
et al. 2005), and exposures are likely episodic 
in nature, so that a single third-trimester 
urine sample may not be representative of 
exposure during all of gestation. However, 
fetal growth and adipocyte replication is rapid 
during the third trimester, indicating that 
it is a relevant exposure period for fat devel-
opment (Dietz 1994). Additionally, studies 
of repeat urinary phthalate measures during 
pregnancy suggest that concentrations of 
phthalate metabolites in a single spot urine 
sample may be moderately predictive of 
DEP, DBP, DiBP, and BzBP concentrations 
throughout pregnancy, with greater variability 
over time for DEHP (Adibi et al. 2008; 
Braun et al. 2012; Ferguson et al. 2014).
Food packaging may account for more 
than half of total DEHP exposure (Rudel 
et al. 2011), and DEHP has consistently been 
detected in foods such as dairy, poultry, and 
cooking oils (Serrano et al. 2014). Although 
we adjusted for maternal prepregnancy BMI 
and adequacy of gestational weight gain, there 
may be residual confounding by maternal food 
preferences that are both a source of prenatal 
phthalate exposures and a cause of increased 
fat mass in offspring. To explain the inverse 
association we observed between ∑DEHP 
and percent fat mass, foods that are part 
of a healthy family diet would also have to 
contain more DEHP. We also did not adjust 
for childhood calorie intake, which is a strong 
predictor of body fat but is not a confounder 
in this study because it occurs temporally after 
maternal third-trimester phthalate exposure. 
Furthermore, if phthalate exposures increase 
adiposity through an effect on the child’s 
ability to regulate hunger, caloric intake may 
be a mediator of associations between prenatal 
phthalate exposures and childhood fat mass.
Although body composition equations 
built into the Tanita scale are not validated 
in children < 7 years, percent fat mass values 
estimated using an equation validated for this 
age group were strongly correlated with the 
values estimated by the proprietary equation. 
Furthermore, associations between phthalate 
metabolite concentrations and percent fat 
mass were consistent across study visits (data 
not shown), and patterns of association were 
similar to those for BMI z-score associations. 
Our sample size was not adequate to examine 
potential critical windows of susceptibility. 
Future studies may consider exploring rela-
tionships between phthalate exposures and 
obesity with respect to differing growth 
trajectories, timing of adiposity rebound, or 
pubertal onset. In addition, we did not have 
information on postnatal phthalate exposures 
and could not examine whether childhood 
phthalate exposures are also related to subse-
quent body fat. Finally, the role of other envi-
ronmental obesogens as potential confounders 
or effect modifiers of associations between 
phthalates and adiposity should be explored in 
future analyses.
This analysis has several important 
strengths. First, we examined exposure to 
phthalates during the hypothesized critical 
window for developmental programming of 
obesity. Second, we incorporated repeated 
measures of fat mass in children. Third, we 
adjusted for many important confounders 
including maternal anthropometric char-
acteristics and multiple measures of socio-
economic status. Fourth, we used a Bayesian 
framework to incorporate prior information 
and account for potential confounding by 
correlated metabolite concentrations. Finally, 
we investigated and accounted for missing 
data in exposures (values < LOD), covariates, 
and outcomes.
Conclusions
In this prospective study, prenatal  exposures to 
phthalates were not associated with increased 
body fat in children age 4–9 years. In tertile 
models, children in the highest tertile of 
maternal third-trimester urinary concen-
trations of ∑DEHP metabolites had lower 
percent fat mass at follow-up compared to 
those in the lowest tertile. Although a substan-
tial cross-sectional literature has assessed 
phthalate metabolite concentrations and 
obesity-related outcomes, larger prospective 
studies examining prenatal exposures are 
needed to replicate these findings.
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